Seroquel Therapy for Substance Use Disorders Comorbid With Schizophrenia
Status:
Completed
Trial end date:
2005-12-01
Target enrollment:
Participant gender:
Summary
It is hypothesized that the atypical antipsychotic, Seroquel, will cause significant
reduction in drug and alcohol cravings in patients with schizophrenia and comorbid cocaine
and/methamphetamine dependence compared to the atypical antipsychotic, risperidone
(Risperdal).
Patients treated with Seroquel will have less use of cocaine and/or methamphetamine as
measured by the Time Line Follow-back, over a 24-week follow-up period.